Research programme: retinal disease therapeutics - Fovea Pharmaceuticals/Sanofi Genzyme

Drug Profile

Research programme: retinal disease therapeutics - Fovea Pharmaceuticals/Sanofi Genzyme

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fovea Pharmaceuticals; Genzyme Corporation
  • Developer Fovea Pharmaceuticals; Sanofi Genzyme
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Retinal disorders

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 31 Dec 2010 This programme is still active
  • 27 Nov 2007 Early research in Retinal disorders in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top